Rocklatan approval tops recent FDA ophthalmology news

From new drugs to new indications for existing drugs, the FDA has approved multiple products in the ophthalmology sphere in the first half of 2019.
Here are the top five most-read FDA approval articles on from January through June:
FDA approves Rocklatan for open-angle glaucoma, ocular hypertension
A fixed-dose combination of netarsudil and latanoprost, Rocklatan — previously known as Roclatan — is designed to target the trabecular meshwork, which is considered the main cause of elevated IOP. Read more.
FDA approves Regeneron’s Eylea for diabetic

Full Story →